Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: PDSP K values Database help » Optimist

Posted by Larry Hoover on January 25, 2005, at 8:50:04

In reply to PDSP K values Database help, posted by Optimist on January 24, 2005, at 18:58:38

> I've been looking at the K values given for different test ligands of specific drugs and am having trouble understanding their meaning.

Just so everyone's on the same page, this is in reference to the database at: http://kidb.cwru.edu/pdsp.php

> For example Tranylcypromine(Parnate) had a K value of >10,000(nM) at the Dopamine D2 receptor.
>
> d-amphetamine has a K value of >10,000 as well for the Dopamine D2 receptor.
>
> Bromocriptine has a K value of 2...
>
> Bupropion(Wellbutrin) has a K value of >100,000...
>
> Olanzapine(Zyprexa) has a K value of 31...
>
> So I'm a little confused on what the K value means. Does a higher number mean more dopamine being bound to the post-synaptic D2 receptor, or vice versa? Or is it something totally different?

The Ki is the concentration [in nM (nanomolar), which is crudely parts per billion] at which the test ligand (the drug being considered) binds to the particular receptor *compared to* the binding of the hot ligand (some other drug, or the natural ligand), such that it occupies 50% of the receptors.

It is important, therefore, to find data which are most reflective of the natural human brain. You would get a more reasonable estimate of Ki if the receptor type (headings Species and Source) are 'human' and 'cloned', respectively. Moreover, where possible, make sure that the Hot Ligand is the radioactive form of the natural ligand. That would be represented as e.g. 3H-dopamine. That's radioactive hydrogen (tritium) substituted for natural hydrogen on the dopamine, allowing it to be "counted" accurately. If the drug displaces dopamine from its receptor (at a known receptor concentration), the radioactivity diminishes, allowing them to calculate the 50% occupancy value (taken off a graph, by the way, so it is always an estimate).

There's more to consider, though. Binding itself is only part of the effect of a drug. This table tells you nothing about the effect of the drug when it is bound to the receptor.

After it binds, the drug might do nothing. That makes it a pure antagonist. It's like somebody parking in your parking spot. You can't use it. Or, the drug could stimulate the receptor just as if the natural ligand was present. That is agonism. Agonism comes in many flavours. A partial agonist does some stimulating, but not as much as the natural ligand. A full agonist is equivalent in stimulation. You can also have agonists that exceed the stimulating effect of the natural ligand (at the same concentration). And, bizarre as it may sound, it could also be a reverse agonist. A reverse agonist has the opposite effect of the natural ligand.

To further complicate matters, some drugs have differing levels of agonism, depending on their own concentration. In other words, non-linear response to dose.

The hyperlinked references in the right-most column will take you to Pubmed, and a good part of the time, there will be information about the agonism/antagonism issue. If not, you have to try and find out the old-fashioned way (search).

> Also what does the dopamine transporter mean? Is it the amount of dopamine released from the presynaptic terminal?

The dopamine transporter is the pre-synaptic reuptake pump. It recycles dopamine for later use, and removes it from the synapse rapidly. Anything that inhibits it does two things. It exaggerates the effect of the dopamine that was released, and it reduces the amount of dopamine available for later release.

It is the dopamine transporter that is hit by d-amphetamine, for example.

> As well what is the clinical significance of these values? Do they predict any specific treatment response?
>
> Thanks guys,
>
> Brian

Yes, they predict treatment response, but only in the context of the agonism/antagonism process. We also have to know something about what the receptor does in the first place.

A high affinity (low Ki; values in single digits as an example) ligand will always substantially displace the natural ligand, even at very low concentrations. Drugs with lower affinities (high Ki) will have to be taken in stronger doses to have a similar effect. Then, if it is an antagonist, it will have an effect similar to down-regulation of the receptor. If it an agonist, however, it stimulates the receptor even in the absence of the normal ligand. That is analogous to up-regulation, and/or activation of the receptor. You need both parts of the relationship to predict the clinical effect of the drug.

And, just to add another conditional element to these considerations.....we know that there are genetic differences in the chemical makeup of the different receptors and transporters. If you've got a mutation in *your* receptors, this information may not apply at all.

Yet another consideration is the metabolic transformation of the drug. The effects of the parent drug often are quite different from the metabolites (some of which are very active themselves).

Lar

 

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Larry Hoover thread:447007
URL: http://www.dr-bob.org/babble/20050124/msgs/447310.html